Neurology Central

AAN 2018: Novel therapy for ‘difficult-to-treat’ migraines revealed

According to a preliminary Phase IIIB LIBERTY trial presented at the American Academy of Neurology’s 70th Annual Meeting (April 21–27, CA, USA), researchers have disclosed that a monoclonal antibody – termed erenumab – could prevent difficult-to-treat migraines in individuals who have tried unsuccessfully to prevent their migraines with other treatments.
To view restricted content, please:

Leave A Comment